StockNews.com Initiates Coverage on Cellectis (NASDAQ:CLLS)

Equities researchers at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Cellectis Trading Down 2.2 %

Shares of CLLS opened at $1.76 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.92 and a current ratio of 1.92. The firm has a market cap of $97.82 million, a P/E ratio of -1.28 and a beta of 3.10. Cellectis has a fifty-two week low of $1.75 and a fifty-two week high of $3.77. The business has a 50-day moving average of $2.11 and a 200 day moving average of $2.29.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The business had revenue of $9.50 million during the quarter, compared to the consensus estimate of $6.00 million. As a group, research analysts forecast that Cellectis will post -0.54 EPS for the current year.

Institutional Trading of Cellectis

Hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. grew its holdings in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after acquiring an additional 12,467 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Cellectis during the second quarter valued at approximately $29,000. Long Focus Capital Management LLC increased its position in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the period. Finally, First Affirmative Financial Network bought a new stake in shares of Cellectis during the 3rd quarter valued at about $45,000. 63.90% of the stock is owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.